Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The role of radiation therapy in children with acute lymphoblastic leukemia kidney infiltration.

Medical and pediatric oncology·2001

Same author

Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes.

International journal of radiation oncology, biology, physics·2001

Same author

Spinal cord compression, infection, and unknown primary cancers.

American journal of clinical oncology·2001

Same author

High-grade carcinoma of the prostate: a comparison of current local therapies.

Urology·2001

Same author

Back to the future: reexploring radiotherapy for benign disease.

Frontiers of radiation therapy and oncology·2001

Same author

The American Cancer Center.

American journal of clinical oncology·2001

Search research articles

Related Experiment Video

Updated: Jul 29, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Prostate-specific antigen-all that rises is not refractory.

B L Hintz¹, A Van Nieuwenhuize, A R Kagan

¹Department of Radiation Oncology, Southern California Permanente Medical Group, Los Angeles, California, USA.

|May 19, 2001

Summary

A rising prostate-specific antigen (PSA) in prostate cancer patients on androgen suppression can indicate treatment resistance. This case shows a patient whose PSA declined with bicalutamide despite initial resistance.

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Jul 29, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Area of Science:

Oncology
Endocrinology

Background:

Androgen suppression therapy is a standard treatment for prostate cancer.
Serum prostate-specific antigen (PSA) levels typically decrease with androgen suppression.
A rise in PSA during treatment often suggests the development of hormone-refractory prostate cancer.

Observation:

A patient receiving depot leuprolide for prostate cancer experienced an increase in PSA levels.
This patient also presented with elevated testosterone levels, which is unusual during androgen suppression therapy.

Findings:

The patient's rising PSA and testosterone levels initially suggested treatment resistance.
However, subsequent administration of bicalutamide led to a decline in PSA levels.

Implications:

This case highlights a potential alternative treatment response in advanced prostate cancer.
It suggests that bicalutamide may be effective even when initial androgen suppression appears to fail.
Further investigation into such paradoxical responses could refine treatment strategies for hormone-refractory prostate cancer.